VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 333 filers reported holding VALEANT PHARMACEUTICALS INTL in Q4 2016. The put-call ratio across all filers is 1.34 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $118,000 | +49.4% | 3,854 | 0.0% | 0.00% | +50.0% |
| Q1 2018 | $79,000 | -21.8% | 3,854 | 0.0% | 0.00% | -33.3% |
| Q4 2017 | $101,000 | +46.4% | 3,854 | 0.0% | 0.00% | +50.0% |
| Q3 2017 | $69,000 | -36.7% | 3,854 | -31.1% | 0.00% | -33.3% |
| Q4 2016 | $109,000 | -28.3% | 5,592 | +18.7% | 0.00% | -57.1% |
| Q3 2016 | $152,000 | -49.0% | 4,713 | +276.1% | 0.01% | -46.2% |
| Q3 2015 | $298,000 | +1652.9% | 1,253 | +1153.0% | 0.01% | +1200.0% |
| Q4 2014 | $17,000 | +13.3% | 100 | 0.0% | 0.00% | 0.0% |
| Q3 2014 | $15,000 | +15.4% | 100 | 0.0% | 0.00% | 0.0% |
| Q2 2014 | $13,000 | -98.0% | 100 | -97.8% | 0.00% | -95.5% |
| Q1 2014 | $654,000 | +16.6% | 4,500 | 0.0% | 0.02% | +29.4% |
| Q4 2013 | $561,000 | +37.5% | 4,500 | +18.4% | 0.02% | +30.8% |
| Q3 2013 | $408,000 | +40.7% | 3,800 | +18.8% | 0.01% | +44.4% |
| Q2 2013 | $290,000 | – | 3,200 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 5,577,892 | $994,984,000 | 31.62% |
| Ruane, Cunniff & Goldfarb | 33,922,192 | $6,051,041,000 | 31.06% |
| LeVasseur Capital Partners LLC | 162,394 | $28,968,000 | 29.76% |
| FARLEY CAPITAL L.P. | 192,130 | $34,272,000 | 27.18% |
| Pershing Square Capital Management | 19,473,933 | $3,473,760,000 | 24.90% |
| Arrow Capital Management, LLC | 109,461 | $19,525,000 | 16.53% |
| Marble Arch Investments | 1,196,900 | $213,503,000 | 16.43% |
| Tesuji Partners | 1,368,040 | $244,414,000 | 15.82% |
| ValueAct Holdings | 14,994,261 | $2,674,676,000 | 15.55% |
| Hound Partners | 3,898,648 | $695,441,000 | 15.04% |